Aggressive lipid-lowering therapy after percutaneous coronary intervention – for whom and how?
Original Research | By PM Ridker, DL Bhatt, AD Pradhan et al.
BACKGROUND - Inflammation and hyperlipidaemia jointly contribute to atherothrombotic disease. However, when people are treated with intensive statin therapy, the relative contributions of inflammation and hyperlipidaemia to the risk of future cardiovascular events might change, which has implications for the choice of adjunctive cardiovascular therapeutics. We aimed to evaluate the relative importance of high-sensitivity C-react...
Original Research | By J Zhang, J Kan, S-L Chen et al.
BACKGROUND — The differential treatment effect of pulmonary artery denervation (PADN) in pulmonary arterial hypertension (PAH) patients with different risk burdens remains unclear. This study aimed to determine the effectiveness of PADN in low vs. intermediate-high-risk PAH patients. METHODS — In total, 128 patients with treatment naive PAH included in the PADN-CFDA trial were categorize...
Definitions and classifications of bifurcation lesions and treatment
Consensus | By R Albiero, F Burzotta, JFl Lassen et al.
Stepwise layered provisional stenting (PS) is the most commonly used strategy to treat coronary bifurcation lesions (CBL). The term “stepwise layered” emphasises the versatility of this approach that allows the adjustment of the procedure plan according to the CBL complexity, starting with stent implantation in one branch and implantation of a second stent in the other branch only when required. A series of refinements have been implem...